The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors.
Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care.
LLS invites Letters of Intent for the Equity in Access Research Program under the Request for Proposals:
Building Evidence for Effective Interventions to Increase Therapeutic Cancer Clinical Trial Accrual: Promoting Access for Patients from Underrepresented Groups
Deadlines:
- Required Letter of Intent: Sep. 12, 2024
- Invited Full Application: Jan. 30, 2025
LLS welcomes Principal Investigators at all stages of their careers as well as Principal Investigators who have not previously conducted research in the area of blood cancer. However, if the Principal Investigator is an early investigator, a more experienced Co-Principal Investigator is required.
The Principal Investigator and other study team members may come from a variety of disciplines, including but not limited to medicine/oncology, nursing, social work, public health, health services research, economics, sociology, health communication, epidemiology, and biostatistics. We strongly encourage multi-disciplinary teams.
Maximum project period is 5 years, and the maximum funding amount per year is $500,000.